Cheng Boyle C, Swink Isaac R, Cheng Cooper T, Corcoran Owen G, Wang Vicki Z, McClain Edward J, Vyas Praveer S, Owen Izzy, Xu Chen, Altman Daniel T, Yu Alexander K
Neuroscience Institute, Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA 15212, USA.
Department of Neurosurgery, Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA 15212, USA.
Bioengineering (Basel). 2024 Sep 6;11(9):898. doi: 10.3390/bioengineering11090898.
P-15 is a 15-amino-acid-long biomimetic peptide widely demonstrated to enhance osteogenesis in vivo. Despite the prevalence of polyether-ether-ketone (PEEK) in interbody device manufacturing, a growing body of evidence suggests it may produce an unfavorable immune response. The purpose of this preliminary study was to characterize the immune response and new bone growth surrounding PEEK implants with and without a P-15 peptide-based osteobiologic. A bilateral femoral defect model was conducted using New Zealand white rabbits. A total of 17 test subjects received one implant in each distal femur, either with or without bone graft material. Animals were allowed to survive to 4 or 8 weeks, at which time the femurs were collected and subjected to micro-computer tomography (microCT) or cytokine analysis. MicroCT analysis included the quantification of bone growth and density surrounding each implant. The cytokine analysis of periprosthetic tissue homogenates included the quantification of interleukins (ILs) and TNF-α expression via ELISA kits. Improvements in bone volume were observed in the P-15 cohort for the regions of interest, 500-136 and 136-0 µm from the implant surface, at 8 weeks post-op. Concentrations of IL-1β, IL-4, and IL-6 cytokines were significantly higher in the P-15 cohort compared to the PEEK cohort at the 4-week timepoint. Significant reductions in the concentrations of IL-4 and IL-6 cytokines from the 4- to 8-week cohort were observed in the P-15 cohort only. The P-15 peptide has the potential to modulate the immune response to implanted materials. We observed improvements in bone growth and a more active micro-environment in the P-15 cohort relative to the PEEK control. This may indicate an earlier transition from the inflammatory to remodeling phase of healing.
P-15是一种由15个氨基酸组成的仿生肽,在体内广泛被证明可促进骨生成。尽管聚醚醚酮(PEEK)在椎间融合器制造中很普遍,但越来越多的证据表明它可能产生不良免疫反应。本初步研究的目的是表征有无基于P-15肽的骨生物制剂的PEEK植入物周围的免疫反应和新骨生长情况。使用新西兰白兔建立双侧股骨缺损模型。总共17只受试动物在每侧股骨远端各植入一个植入物,植入物带有或不带有骨移植材料。让动物存活4周或8周,届时收集股骨并进行微型计算机断层扫描(microCT)或细胞因子分析。MicroCT分析包括量化每个植入物周围的骨生长和骨密度。假体周围组织匀浆的细胞因子分析包括通过酶联免疫吸附测定(ELISA)试剂盒量化白细胞介素(ILs)和肿瘤坏死因子-α(TNF-α)的表达。术后8周时,在P-15组中观察到感兴趣区域(距植入物表面500-136和136-0 µm)的骨体积有所改善。在4周时间点,P-15组中IL-1β、IL-4和IL-6细胞因子的浓度显著高于PEEK组。仅在P-15组中观察到从4周组到8周组IL-4和IL-6细胞因子浓度显著降低。P-15肽有可能调节对植入材料的免疫反应。相对于PEEK对照组,我们在P-15组中观察到骨生长改善和更活跃的微环境。这可能表明愈合过程从炎症阶段到重塑阶段的过渡更早。